A clinical dilemma about a new oral anticoagulant treatment

Atrial fibrillation (AF) is the most common chronic cardiac arrhythmia (1, 2). Major mortality and morbidity are associated with stroke and systemic embolism in patients with AF (3). The CHA2DS2- VASc is a clinical score for estimating the risk of stroke in patients with non-valvular AF and is used to determine whether anticoagulation therapy treatment is required or not (2-4). The numerous limitations of the clinical usage of warfarin have led clinicians to search for alternative agents. New oral anticoagulants (NOACs), such as dabigatran, appear to be preferable in these patients (5, 6). Herein, we present a patient with acute ischemic stroke (AIS) occurring under dabigatran treatment, causing fainting, which resulted in a traumatic large lower leg hematoma.